Literature DB >> 27270078

Parthenolide ameliorates Concanavalin A-induced acute hepatitis in mice and modulates the macrophages to an anti-inflammatory state.

Dan Wang1, Huafeng Wang2, Shuyu Fu3, Xixi Cheng3, Fengrui Yang3, Qi Zhang3, Yan Li3, Zhenyi Xue3, Lijuan Zhang3, Wenjing Huang4, Luhong Yang2, Dongchen Na2, Yurong Da3, Ying Kong5, Rongxin Zhang6.   

Abstract

Parthenolide, the principal sesquiterpene lactone present in medicinal plants such as feverfew, has anti-microbial, anti-inflammatory and anticancer activities. In the present study, we investigated the protective role of parthenolide against acute hepatitis in mice. Mice acute hepatitis were induced by Concanavalin A and treated by parthenolide in vivo. Results shown that parthenolide remarkably reduced the congestion and necroinflammation of the mice livers with Concanavalin A-induced acute hepatitis. Meanwhile, parthenolide treatment recover the liver function which indicated by decreased the serum alanine transaminase and alkaline phosphatase activities and promoted the expression of Ki67 in the livers of these mice. In addition, parthenolide administration suppressed the Concanavalin A-induced immune reaction, as indicated by the number of F4/80, CD49b and CD4 cells present in the liver. Furthermore, parthenolide also significantly reduced the expression of pro-inflammatory cytokines such as IFN-γ, TNF-α, IL-17A, IL-1β and IL-6 in lipopolysaccharide (LPS)-stimulated RAW264.7 cells in vitro. Moreover, parthenolide exposure decreased the phosphorylation of STAT3 and p38, and promoted the phosphorylation of p53 in RAW264.7 cells in vitro. In conclusion, parthenolide represents a drug candidate to protect the liver against Concanavalin A-induced acute hepatitis. The possible molecular mechanism involves the anti-inflammatory effects of parthenolide may by suppressing the STAT3/p38 signals and enhanced the p53 signals.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute hepatitis; Macrophage; Parthenolide; STAT3

Mesh:

Substances:

Year:  2016        PMID: 27270078     DOI: 10.1016/j.intimp.2016.05.024

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  6 in total

1.  Parthenolide plays a protective role in the liver of mice with metabolic dysfunction‑associated fatty liver disease through the activation of the HIPPO pathway.

Authors:  Weihong Wang; Yukai He; Qiuli Liu
Journal:  Mol Med Rep       Date:  2021-05-06       Impact factor: 2.952

2.  Treatment of Non-Alcoholic Steatosis: Preclinical Study of a New Nutraceutical Multitarget Formulation.

Authors:  Laura Micheli; Alessandra Pacini; Lorenzo Di Cesare Mannelli; Elena Trallori; Roberta D'Ambrosio; Carlo Bianchini; Pietro Lampertico; Carla Ghelardini
Journal:  Nutrients       Date:  2020-06-18       Impact factor: 5.717

Review 3.  Summary of Natural Products Ameliorate Concanavalin A-Induced Liver Injury: Structures, Sources, Pharmacological Effects, and Mechanisms of Action.

Authors:  Sabrin R M Ibrahim; Alaa Sirwi; Basma G Eid; Shaimaa G A Mohamed; Gamal A Mohamed
Journal:  Plants (Basel)       Date:  2021-01-25

4.  Downregulation of the enhancer of zeste homolog 1 transcriptional factor predicts poor prognosis of triple-negative breast cancer patients.

Authors:  Wei Peng; Wei Tang; Jian-Di Li; Rong-Quan He; Jia-Yuan Luo; Zu-Xuan Chen; Jiang-Hui Zeng; Xiao-Hua Hu; Jin-Cai Zhong; Yang Li; Fu-Chao Ma; Tian-Yi Xie; Su-Ning Huang; Lian-Ying Ge
Journal:  PeerJ       Date:  2022-07-12       Impact factor: 3.061

5.  Ratio of Creatine Kinase to Alanine Aminotransferase as a Biomarker of Acute Liver Injury in Dystrophinopathy.

Authors:  Liang Wang; Menglong Chen; Min Xu; Jing Li; Pinning Feng; Ruojie He; Yuling Zhu; Huan Li; Jinfu Lin; Cheng Zhang
Journal:  Dis Markers       Date:  2018-06-19       Impact factor: 3.434

6.  Parthenolide Augments the Chemosensitivity of Non-small-Cell Lung Cancer to Cisplatin via the PI3K/AKT Signaling Pathway.

Authors:  Li-Mei Wu; Xiao-Zhong Liao; Yan Zhang; Zi-Rui He; Shi-Qing Nie; Bin Ke; Lin Shi; Jian-Fu Zhao; Wen-Hui Chen
Journal:  Front Cell Dev Biol       Date:  2021-02-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.